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Introduction
Postmarketing drug surveillance refers to the monitoring of drugs once they
reach the market after clinical trials. It is a critical part of the effort to ensure
that drugs are safe and effective. Clinical trials, which are used to test the
safety and efficacy of new drugs, are, by their very nature, limited. They 
generally involve evaluating drugs on a small number of people over a limited
time frame under controlled conditions. Postmarketing drug surveillance 
evaluates drugs taken by a wide variety of people under a wide range of 
circumstances over an extended period of time. Such surveillance, given its
more expansive evaluation, is much more likely to detect any undiscovered
effects, positive and negative, that may be associated with a drug.
The Food and Drug Administration (FDA), the primary entity responsible
for monitoring postmarketing drug surveillance, relies mainly on reports
generated by pharmaceutical companies, physicians, and ongoing studies of
drugs once they reach the marketplace. This approach has been helpful in
detecting both adverse drug events as well as unintended benefits; however,
a more systematic one may be more effective. For example, better surveillance
may have discovered the problems with the statin Baycol earlier and reduced
the number of people who developed severe and deadly side effects. Conversely,
postmarketing studies have also recently provided some indications that
statins may have a beneficial effect on a variety of conditions, including
cancer and Alzheimer’s disease.
Nevertheless, the current system is fragmented and relies to a large extent on
voluntary reporting. Given the ever increasing use of prescription drugs,
coupled with an aging population, a streamlined and integrated 
postmarketing drug surveillance system would better detect any unintended
effects. This issue brief discusses the importance of postmarketing drug 
surveillance and suggests one way that the current system can be revamped to
benefit the federal government, pharmaceutical companies, and, most 
importantly, the patients who depend on drugs to be safe and effective.
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Postmarketing drug surveillance monitors the safety
of medicines being used by patients upon prescription
by a medical provider. It is the phase four of a clinical
trial and takes place after the FDA has approved a
drug for marketing. A drug is approved after it has
passed through three phases of clinical trials, which
are designed to test safety and efficacy. These first
three phases usually total about 3,000 patients and are
generally conducted under strictly defined conditions
in a limited time frame. The limited number of people
used in clinical trials is due to time and cost constraints
of developing a drug. The Tufts Center for the
Study of Drug Development estimates that the
average cost of bringing one new medicine to market
is $802 million1 and that it takes an average of 12 to
15 years to discover and develop a new medicine.2
Other studies estimate the costs to be even higher.
Phase four of a clinical trial is key to evaluating the
safety and efficacy of a drug in real-world conditions
over an extended period of time. The FDA is 
primarily responsible for postmarketing surveillance
of drugs in the United States through its MedWatch
program. This entails gathering information from the
pharmaceutical industry, medical providers, and
patients. Pharmaceutical companies operate systems
to monitor their drugs for adverse reactions and 
provide periodic postmarket reports to the FDA.
They also report whenever a serious adverse drug
reaction is detected. The medical community also
plays a voluntary role in reporting adverse drug 
reactions. In addition, the federal government,
pharmaceutical companies, or universities often
conduct ongoing studies after marketing to gather
additional information or to explore further any
negative drug reactions. However, although much has
been done to enhance postmarketing surveillance, the
current system remains fragmented and limited.
Given the growing importance of prescription drugs,
a comprehensive, systematic reporting and monitoring
program would greatly enhance our nation’s capacity
to increase drug safety.
The Importance of Postmarketing 
Drug Surveillance
The use of prescription drugs is increasing every year.
In 2000 in the United States, more than 170 million
people filled 2.2 billion prescriptions, accounting for
over $100 billion in expenditures.3 Given the scope of
use, postmarketing surveillance is critical in tracking
the real-world effects of prescription drugs. As noted
earlier, clinical trials are limited by time and cost
constraints and therefore may fail to detect adverse or
beneficial reactions among users. Even the largest and
most well-designed clinical trials cannot uncover
every problem that may be revealed once a product is
widely used. For example, to detect the possibility of a
severe drug-induced liver injury, which is the most
frequent reason a drug is removed from the market
after approval, a trial would require upwards of 30,000
people. Postmarketing drug surveillance is therefore
critical to ensuring that a medication is safe for use by
a wide variety of people (i.e., varying ages, genders,
races, lifestyles, etc.) under a wide range of circum-
stances (i.e., people with comorbidities or on multiple
drugs, with varying nutritional status, taking       over-
the-counter supplements, etc.). Adverse drug reac-
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tions are a major reason for the importance of post-
marketing drug surveillance, and although the current
system is focused on detecting adverse drug reactions,
it is not comprehensive. Most people     consider
adverse drug reactions to be underreported.
There remain significant problems of underrepresen-
tation in clinical trials, especially of older people, who
tend to use the most drugs and are also more liable to
suffer from adverse drug reactions.4 Unfortunately, too
little is known about the effects of drugs on older
people, and it has been estimated that as many as 35
percent of people over 65 experience adverse drug
reactions each year.5 Postmarketing surveillance is
therefore critical to detecting any negative effects in
this population and intervening promptly to reduce
such situations.
Often little is known about the effects of drugs in
younger populations. For example, there has been
much concern about the use of some antidepres-
sants in children as young as age 3. A recent study
has found that such drugs are barely effective in this
population.6 Moreover, since individuals of this age
are not commonly chosen to participate in clinical
trials, very little is known about the effects of such
drugs on the developing brain. However, there is
strong evidence that they play a role in suicide among
adolescents. In fact, British regulators have advised
physicians to stop prescribing almost all antidepres-
sants to children under 18.
Another component involves the use of drugs over an
extended period of time. Since most clinical trials are
for a limited time period, information regarding
long-term effects is scarce. Indeed, some physicians
are worried about the long-term effects of 
cholesterol-lowering statins on muscles. Thorough,
ongoing surveillance systems are therefore critical in
responding to these concerns.
Conversely, it should also be noted that clinical trials
may not detect unforeseen benefits of a new drug.
Statins are a good example. Developed to lower 
cholesterol, they may also have beneficial effects, some
believe, in forestalling some cancers, Alzheimer’s   dis-
ease, multiple sclerosis, and other conditions.
Another factor in the importance of postmarketing
surveillance stems from efforts to expedite the drug
approval process. In an effort to bring potentially life-
saving drugs to the market sooner while also reducing
the costs of drug development, the FDA has been
working to expedite drug approvals. Former
Commissioner Mark McClellan outlined a series of
steps designed to improve the prescription drug
approval process, including efforts to reduce the
number of new drugs that must be reviewed more
than one time; review the costs of agency 
regulations, conducting an external independent
review of the FDA’s entire approval process; and other
measures. While these efforts are laudable, they
simultaneously enhance the importance of 
postmarketing surveillance. If a drug reaches the
market more quickly, again regardless of the 
soundness of the clinical trials, less may be known
about its potential effects. Thus the need for 
continued review of these drugs is critical. Indeed,
McClellan recognized this need and made learning
more about benefits and side effects of drugs after
approval a priority for the FDA.
Other important reasons for expanding and 
enhancing postmarketing drug surveillance include:
• Unapproved or off-label usage:
This routine practice by physicians of prescribing
drugs to patients to treat conditions for which the
drug was not tested can be very useful, but keeping
track of the effects of this practice is critical.
• Increased use of international clinical trials:
Some pharmaceutical companies have increased the 
number of clinical trials conducted abroad in order
to reduce costs. This has raised concerns about the
stringency of trial procedures, appropriate 
documentation of outcomes, and other matters 
critical to a well-conducted clinical trial. Although
the legitimacy of these claims is not well
understood, postmarketing surveillance is critical to 
compensating for potential flaws in these 
international clinical trials. Of course, eliminating
the practice altogether would be the best 
alternative.
• Reduced conflicts of interest in academia:
There has been concern about the relationships
between academic researchers, universities, and 
pharmaceutical companies when the pharmaceuti-
4 Improving Drug Safety: The Importance of  Postmarketing Drug Surveillance
cal industry sponsors studies. One comprehensive
study of potential conflicts of interest in the
biomedical field found that industry-sponsored
research is more likely to have results more favor-
able to the company that funded the research.7 A
national postmarketing surveillance system could
help eliminate the conflicts of interest that can arise
with specific research endeavors.
Recommendations
One way to enhance a postmarketing surveillance
system would be to establish regional centers to be
responsible for monitoring new drugs that come on
the market. The Department of Health and Human
Services (DHHS) is currently organized into ten
regions in the United States. A system funded by the
government and the pharmaceutical industry that
selects an academic medical center in each region
through a competitive process to be responsible for
monitoring prescription drug use would help ensure a
more integrated postmarketing surveillance system.
The National Institutes of Health (NIH), alone or in
collaboration with the FDA, could plan the
coordination and carry out the reviewing process.
This is not an entirely new concept; indeed Raymond
Woosley, a research physician at Georgetown
University, proposed years ago that 15 centers of
education and research be created to test the safety,
efficacy, and cost-effectiveness of prescription drugs.
There is an effort under way that is a step in this
direction. The Agency for Healthcare Research and
Quality (AHRQ) operates the Centers for Education
and Research on Therapeutics (CERTs) demonstra-
tion program, which is intended to conduct research
and provide education to advance the optimal use of
therapeutics such as prescription drugs. In existence
since 1999, its three goals are to increase awareness of
both the uses and risks of new drugs; to provide
clinical information to patients, health care providers,
and other components of the health care system; and
to improve quality while reducing the cost of care.
CERTs consists of seven research centers and a
coordinating center, as well as partnerships with
various public and private organizations. This
program is still very small, however, receiving less
than $10 million per year. Nevertheless, it serves as a
model for how an effective postmarketing drug
surveillance system can be established.
Another pioneering effort is the Boston Collaborative
Drug Surveillance Program (BCDSP) at Boston
University, under the leadership of Hershel Jick, M.D.
In operation since 1967, BCDSP conducts
epidemiological research to quantify the potential
adverse effects of prescription drugs using large
automated patient databases. Recently, it has been
using medical record data from the United Kingdom
for research purposes as the National Health Service
has been using electronic medical records for years.
The BCDSP exemplifies the effective role that
academic health centers can play in postmarketing
drug surveillance.
There are promising indications that postmarketing
surveillance is becoming a higher priority. The
Prescription Drug User Fee Act, which is intended to
speed up the drug review and approval process by
providing for user fees paid by the pharmaceutical
industry to support such activities, recently was
renewed with a provision that a larger portion of such
fees be used for postmarketing activities. Moreover,
through its recent Roadmap initiative, the NIH has
indicated an interest in developing a national network
for clinical trials that uses standard data protocols.
This will help save resources in designing trials and
facilitate the comparison of data across trials. Such an
effort would presumably benefit phase four trials. In
addition, a key aspect of any postmarketing drug
surveillance involves the use of electronic medical
records. Given the growing use of such records in the
United States, coupled with the Bush administration’s
recent call for the creation of a nationwide electronic
medical records system in the next ten years, the idea
of a comprehensive, integrated postmarketing
surveillance is more feasible.
Conclusion
All parties involved in postmarketing surveillance
would benefit from an expanded, systematic 
postmarketing system. The federal government would
be establishing a streamlined and integrated system to
detect drug reactions and better ensure the safety of
drugs. The pharmaceutical industry, which already
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supports numerous studies to evaluate the safety of
drugs, would benefit from the potential cost savings of
a common, standardized system8 as well as being less
susceptible to liability claims. Physicians, hospi-
tals, and other health care providers would 
benefit from the additional information about drug
safety and efficacy that such a system would entail.
Lastly, and most importantly, patients would benefit
from the improved quality of care that would result
from more comprehensive information about drug
safety and efficacy.
Afterword
By Michael K. Gusmano, Ph.D.
Prescription drugs are a powerful tool for combating
disease and preserving health, but there are risks
associated with pharmaceuticals that cannot be
ignored. A 1998 report in the Journal of the American
Medical Association, for example, estimated that
106,000 fatal drug reactions occur each year. The
expanding use of these drugs demands a comprehen-
sive system to track adverse side effects, investigate
the consequences of long-term use, and compare the
relative efficacy of alternative drugs. As explained in
this issue brief, such a system does not exist. At a time
when Congress should be expanding the capacity of
the Food and Drug Administration to engage in post-
marketing surveillance of drugs, it has instead reduced
the agency’s budget and undermined its   ability to
track drugs after they are approved for   marketing.
As a result, the United States continues to rely on a
disjointed, and largely voluntary, reporting system.
Recently reported health problems associated with
popular Cox-2 inhibitors suggest that this approach is
not serving us well.
Our failure to develop an effective national system of
postmarketing surveillance, combined with efforts to
speed up the initial drug approval process and the
exclusion of children and older adults from clinical
trials, creates a risky situation for the public, the
government, health care providers and the
pharmaceutical industry.
Former Representative Billy Tauzin, now president
of the Pharmaceutical Research and Manufacturers
of America, stated that “it [the pharmaceutical
industry] has to earn the trust and confidence of
consumers again.” Working with the president and
Congress to establish a credible and effective system
of postmarketing surveillance would be a good step
in that direction.
Robert N. Butler, M.D., is president and CEO of the
International Longevity Center-USA.
James P. Nyberg, M.P.A., is director of elder services at
Child and Family Services of Newport County, R.I.
Michael K. Gusmano, Ph.D., is senior research analyst at
the ILC-USA and assistant professor of health policy and
management at Columbia University.
References
1. Tufts Center for the Study of Drug Development.
http://csdd.tufts.edu/. (Accessed December 2004.)
2. PhRMA.org. Why Do Prescription Drugs Cost So Much and Other
Questions About Your Medicines. www.phrma.org/publications/
publications/brochure/questions/questions.pdf. (Accessed
December 2004.)
3. Agency for Healthcare Research and Quality. 2004. Statistical
Brief #21: Trends in Outpatient Prescription Drug Utilization and
Expenditures: 1997–2000. June 2004. Rockville, MD: Agency for
Healthcare Research and Quality.
4. Butler, Robert N., and James Nyberg. 2002. Clinical Trials and
Older Persons: The Need for Greater Representation. New York:
International Longevity Center.
5. International Longevity Center. 2000. A National Crisis: The
Need for Geriatrics Faculty Training and Development: Toward
Functional Independence in Old Age. New York: International
Longevity Center.
6. Jureidini, Jon N., Christopher J. Doecke, Peter R. Mansfield et
al. 2004. Efficacy and safety of antidepressants for children and
adolescents. BMJ 328:879–83.
7. Bekelman, Justin E., Yan Li, and Cary P. Gross. 2003. Scope
and impact of financial conflicts of interest in biomedical research.
JAMA 289:454–65.
8. Michell, Allen A. 2003. Systematic identification of drugs that
cause birth defects—a new opportunity. N Engl J Med 349:2556–9.
Copyright © 2004 International Longevity Center–USA, Ltd. All rights reserved. IB13-2004
The International Longevity Center–USA
(ILC–USA) is a not-for-profit, nonpartisan
research, education, and policy organization
whose mission is to help individuals and societies
address longevity and population aging in
positive and productive ways, and highlight older
people’s productivity and contributions to their 
families and society as a whole.
The organization is part of a multinational
research and education consortium, which
includes centers in the United States, Japan,
Great Britain, France, and the Dominican
Republic. These centers work both
autonomously and collaboratively to study
how greater life expectancy and increased
proportions of older people impact nations
around the world.
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